Advertisement

CD30-Positive Lymphoproliferative Disorders

  • Liana NikolaenkoEmail author
  • Jasmine Zain
  • Steven T. Rosen
  • Christiane Querfeld
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 176)

Abstract

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Both LyP and pcALCL show numerous clinical, histological and immunophenotypic variants, and generally have an indolent course with a favorable prognosis. Overlapping features of LyP and pcALCL with other CD30+ T-cell lymphomas, inflammatory, and/or infectious conditions emphasize the importance of careful clinicopathologic correlation and staging.

Keywords

CD30+ lymphoproliferative disorder Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma Borderline lesions Cutaneous T-cell lymphoma Extensive limb disease Therapeutic targets 

References

  1. 1.
    Willemze R, Meijer CJ (2003) Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 17(1319–1332):vii–viiiCrossRefGoogle Scholar
  2. 2.
    Bekkenk MW, Geelen FA, van Voorst Vader PC et al (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661PubMedGoogle Scholar
  3. 3.
    Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785CrossRefGoogle Scholar
  4. 4.
    Stein H, Mason DY, Gerdes J et al (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858PubMedGoogle Scholar
  5. 5.
    Falini B, Pileri S, Pizzolo G et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1–14PubMedGoogle Scholar
  6. 6.
    Assaf C, Hirsch B, Wagner F et al (2007) Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol 127:1898–1904CrossRefGoogle Scholar
  7. 7.
    Dupont A, Thulliez A (1956) Histio-monocytic reticulosis and mycosis fungoides; four case reports. Arch Belg Dermatol Syphiligr 12:263–272Google Scholar
  8. 8.
    Macaulay WL (1968) Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign–histologically malignant. Arch Dermatol 97:23–30CrossRefGoogle Scholar
  9. 9.
    Kempf W (2006) CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 33(Suppl 1):58–70CrossRefGoogle Scholar
  10. 10.
    Pujol RM, Muret MP, Bergua P, Bordes R, Alomar A (2005) Oral involvement in lymphomatoid papulosis. Report of two cases and review of the literature. Dermatology 210:53–57CrossRefGoogle Scholar
  11. 11.
    Scarisbrick JJ, Evans AV, Woolford AJ, Black MM, Russell-Jones R (1999) Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol 141:1125–1128CrossRefGoogle Scholar
  12. 12.
    Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM (2010) Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 24:574–587PubMedGoogle Scholar
  13. 13.
    Wieser I, Wohlmuth C, Nunez CA, Duvic M (2016) Lymphomatoid papulosis in children and adolescents: a systematic review. Am J Clin Dermatol 17:319–327CrossRefGoogle Scholar
  14. 14.
    Sauder MB, O’Malley JT, LeBoeuf NR (2017) CD30+ lymphoproliferative disorders of the skin. Hematol Oncol Clin North Am 31:317–334CrossRefGoogle Scholar
  15. 15.
    Cordel N, Tressieres B, D’Incan M et al (2016) Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist 21:76–83CrossRefGoogle Scholar
  16. 16.
    Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M (2016) Primary cutaneous CD30(+) lymphoproliferative disorders. J der Dtsch Dermatol Ges = J Ger Soc Dermatol JDDG 14:767–782Google Scholar
  17. 17.
    Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES (2005) Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 8:52–60CrossRefGoogle Scholar
  18. 18.
    Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30+ cutaneous lymphoproliferative disorders: the stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49:1049–1058CrossRefGoogle Scholar
  19. 19.
    Booken N, Goerdt S, Klemke CD (2012) Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the mannheim cutaneous lymphoma registry. J der Dtschn Dermatol Ges = J Ger Soc Dermatol JDDG 10:331–339Google Scholar
  20. 20.
    Woo DK, Jones CR, Vanoli-Storz MN et al (2009) Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 145:667–674CrossRefGoogle Scholar
  21. 21.
    Benner MF, Willemze R (2009) Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 145:1399–1404CrossRefGoogle Scholar
  22. 22.
    Kempf W (2017) A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol 34:22–35CrossRefGoogle Scholar
  23. 23.
    El Shabrawi-Caelen L, Kerl H, Cerroni L (2004) Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 140:441–447PubMedGoogle Scholar
  24. 24.
    Saggini A, Gulia A, Argenyi Z et al (2010) A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 34:1168–1175CrossRefGoogle Scholar
  25. 25.
    Kempf W, Kazakov DV, Paredes BE, Laeng HR, Palmedo G, Kutzner H (2013) Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders. Dermatology 227:346–352CrossRefGoogle Scholar
  26. 26.
    Kempf W, Kazakov DV, Baumgartner HP, Kutzner H (2013) Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol 68:809–816CrossRefGoogle Scholar
  27. 27.
    Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefGoogle Scholar
  28. 28.
    Mann KP, Hall B, Kamino H, Borowitz MJ, Ratech H (1995) Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol 19:407–416CrossRefGoogle Scholar
  29. 29.
    Lin JH, Lee JY (2004) Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia. J Cutan Pathol 31:458–461CrossRefGoogle Scholar
  30. 30.
    Wang J, Sun NC, Nozawa Y et al (2001) Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features. Histopathology 39:476–481CrossRefGoogle Scholar
  31. 31.
    Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE (1997) TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 150:1893–1900PubMedPubMedCentralGoogle Scholar
  32. 32.
    Stein H, Foss HD, Durkop H et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695PubMedGoogle Scholar
  33. 33.
    Benner MF, Jansen PM, Meijer CJ, Willemze R (2009) Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 161:121–127CrossRefGoogle Scholar
  34. 34.
    Greisser J, Doebbeling U, Roos M et al (2005) Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 14:380–385CrossRefGoogle Scholar
  35. 35.
    Braun FK, Hirsch B, Al-Yacoub N et al (2010) Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 130:826–840CrossRefGoogle Scholar
  36. 36.
    Stutz N, Johnson RD, Wood GS (2012) The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol 67(1327):e1–e10Google Scholar
  37. 37.
    Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S (2003) Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 37:176–185CrossRefGoogle Scholar
  38. 38.
    van Kester MS, Tensen CP, Vermeer MH et al (2010) Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol 130:563–575CrossRefGoogle Scholar
  39. 39.
    Karai LJ, Kadin ME, Hsi ED et al (2013) Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol 37:1173–1181CrossRefGoogle Scholar
  40. 40.
    Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues 4th edn.Google Scholar
  41. 41.
    Xing X, Feldman AL (2015) Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol 22:29–49CrossRefGoogle Scholar
  42. 42.
    Gratzinger D, Million L, Kim YH (2015) Occult dermal lymphatic involvement is frequent in primary cutaneous anaplastic large cell lymphoma. Am J Dermatopathol 37:767–770CrossRefGoogle Scholar
  43. 43.
    Kerschmann RL, Berger TG, Weiss LM et al (1995) Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage. Arch Dermatol 131:1281–1288CrossRefGoogle Scholar
  44. 44.
    Xue D, Li X, Ren Y, Liu Q, Yen Y, Xue L (2015) Primary cutaneous anaplastic large cell lymphoma with positive ALK expression and a rapidly progressive cutaneous nodule. Int J Surg Pathol 23:333–335CrossRefGoogle Scholar
  45. 45.
    Uzuncakmak TK, Akdeniz N, Karadag AS, Taskin S, Zemheri EI, Argenziano G (2017) Primary cutaneous CD30(+) ALK(-) anaplastic large cell lymphoma with dermoscopic findings: a case report. Dermatol Prac Concept 7:59–61Google Scholar
  46. 46.
    De Souza A, Tinguely M, Burghart DR, Berisha A, Mertz KD, Kempf W (2016) Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages. J Cutan Pathol 43:579–588CrossRefGoogle Scholar
  47. 47.
    Paul MA, Krowchuk DP, Hitchcock MG, Jorizzo JL (1996) Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 13:501–506CrossRefGoogle Scholar
  48. 48.
    Kempf W, Pfaltz K, Vermeer MH et al (2011) EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118:4024–4035CrossRefGoogle Scholar
  49. 49.
    Bilgic Temel A, Unal B, Erdi Sanli H, Duygulu S, Uzun S (2017) A severe case of lymphomatoid papulosis type E successfully treated with interferon-alfa 2a. Case Rep Dermatol Med 2017:3194738PubMedPubMedCentralGoogle Scholar
  50. 50.
    Thomsen K, Wantzin GL (1987) Lymphomatoid papulosis. A follow-up study of 30 patients. J Am Acad Dermatol 17:632–636CrossRefGoogle Scholar
  51. 51.
    Wantzin GL, Thomsen K (1982) PUVA-treatment in lymphomatoid papulosis. Br J Dermatol 107:687–690CrossRefGoogle Scholar
  52. 52.
    Lange-Wantzin G, Thomsen K, Hou-Jensen K (1984) Lymphomatoid papulosis: a follow-up study. Acta Derm Venereol 64:46–51PubMedGoogle Scholar
  53. 53.
    Volkenandt M, Kerscher M, Sander C, Meurer M, Rocken M (1995) PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol 131:1094CrossRefGoogle Scholar
  54. 54.
    Errichetti E, Piccirillo A, Ricciuti F, Ricciuti F (2013) Steroid-resistant localized lymphomatoid papulosis treated with local bath-PUVA therapy. Indian J Dermatol 58:163CrossRefGoogle Scholar
  55. 55.
    Bruijn MS, Horvath B, van Voorst Vader PC, Willemze R, Vermeer MH (2015) Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch cutaneous lymphoma group. Br J Dermatol 173:1319–1322CrossRefGoogle Scholar
  56. 56.
    Vonderheid EC, Sajjadian A, Kadin ME (1996) Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34:470–481CrossRefGoogle Scholar
  57. 57.
    Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R (2015) Results of a phase II trial of brentuximab vedotin for CD30+ Cutaneous T-Cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33:3759–3765CrossRefGoogle Scholar
  58. 58.
    Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R (2004) Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 150:1198–1201CrossRefGoogle Scholar
  59. 59.
    Oliveira A, Fernandes I, Alves R, Lima M, Selores M (2011) Primary cutaneous CD30 positive anaplastic large cell lymphoma–report of a case treated with bexarotene. Leuk Res 35:e190–e192CrossRefGoogle Scholar
  60. 60.
    Ardigo M, Marulli GC, Cota C, Mastroianni A, Berardesca E (2007) Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. J Drugs Dermatol JDD 6:216–219PubMedGoogle Scholar
  61. 61.
    Qiu B, Chen M (1996) Treatment of cutaneous T cell lymphoma with low doses of interferon alpha-2b. Chin Med J (Engl) 109:404–406Google Scholar
  62. 62.
    Yokoi I, Ishikawa E, Koura A et al (2014) Successful treatment of primary cutaneous anaplastic large cell lymphoma with intralesional methotrexate therapy. Acta Derm Venereol 94:319–320CrossRefGoogle Scholar
  63. 63.
    Querfeld C, Kuzel TM, Guitart J, Rosen ST (2007) Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncol 21:689–696; discussion 99–700 (Williston Park)Google Scholar
  64. 64.
    Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ (1989) Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 20:416–428CrossRefGoogle Scholar
  65. 65.
    Beljaards RC, Kaudewitz P, Berti E et al (1993) Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients. Cancer 71:2097–2104CrossRefGoogle Scholar
  66. 66.
    Yu JB, McNiff JM, Lund MW, Wilson LD (2008) Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 70:1542–1545CrossRefGoogle Scholar
  67. 67.
    Gentile MS, Martinez-Escala ME, Thomas TO et al (2015) Single-fraction radiotherapy for CD30(+) lymphoproliferative disorders. Biomed Res Int 2015:629587CrossRefGoogle Scholar
  68. 68.
    Horwitz SM, Kim YH, Foss F et al (2012) Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119:4115–4122CrossRefGoogle Scholar
  69. 69.
    Krathen RA, Ward S, Duvic M (2003) Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206:142–147CrossRefGoogle Scholar
  70. 70.
    Cervigon-Gonzalez I, Torres-Iglesias LM, Palomo-Arellano A, Gil-Pascual B (2011) Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox. Case Rep Dermatol 3:13–17CrossRefGoogle Scholar
  71. 71.
    Scarisbrick JJ, Morris S, Azurdia R et al (2013) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168:192–200CrossRefGoogle Scholar
  72. 72.
    French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH (2001) Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 45:914–918CrossRefGoogle Scholar
  73. 73.
    Kim YH, Whittaker S, Horwitz SM et al (2016) Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician’s choice (Methotrexate or Bexarotene): the phase 3 alcanza study. Am Soc Hematology, 2016Google Scholar
  74. 74.
    Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N (2006) Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7:51–58CrossRefGoogle Scholar
  75. 75.
    Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R (1992) Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 127:524–528CrossRefGoogle Scholar
  76. 76.
    Boudova L, Kazakov DV, Jindra P et al (2006) Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56 + anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol 33:584–589CrossRefGoogle Scholar
  77. 77.
    Wu JJ, Guitart J, Tucker RM, Kuzel TM, Rosen ST (2003) Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol 42:464–465CrossRefGoogle Scholar
  78. 78.
    Akpek G, Koh HK, Bogen S, O’Hara C, Foss FM (1999) Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86:1368–1376CrossRefGoogle Scholar
  79. 79.
    Chao-Lo MP, King-Ismael D, Lopez RA (2008) Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep 2:31–34CrossRefGoogle Scholar
  80. 80.
    Wehkamp U, Oschlies I, Nagel I et al (2015) ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol 42:870–877CrossRefGoogle Scholar
  81. 81.
    Meier F, Schaumburg-Lever G, Kaiserling E, Scheel-Walter HG, Scherwitz C (1992) Primary cutaneous large-cell anaplastic (Ki-1) lymphoma in a child. J Am Acad Dermatol 26:813–817CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Liana Nikolaenko
    • 1
    Email author
  • Jasmine Zain
    • 1
    • 4
  • Steven T. Rosen
    • 1
    • 4
  • Christiane Querfeld
    • 2
    • 3
    • 4
  1. 1.Department of Hematology and Hematopoietic Cell TransplantationCity of Hope National Medical CenterDuarteUSA
  2. 2.Division of DermatologyCity of Hope National Medical CenterDuarteUSA
  3. 3.Department of PathologyCity of Hope National Medical CenterDuarteUSA
  4. 4.Toni Stephenson Lymphoma CenterCity of Hope National Medical CenterDuarteUSA

Personalised recommendations